GPO IDN video laryngoscope procurement in the USA is the single most important commercial reality any distributor entering the U.S. hospital market must understand. Most medical devices cannot reach U.S. hospitals without navigating group purchasing organizations and integrated delivery networks. As Occam Design’s market access guide states directly, there is no path to market for most medical devices without networking with IDNs, GPOs, and hospital systems.
This guide explains how GPOs and IDNs control U.S. hospital purchasing, how the procurement process works for a video laryngoscope, and what distributors must do to sell effectively in GPO-contracted and non-contracted environments.
What a GPO is and why it controls hospital purchasing
A Group Purchasing Organization is an entity that aggregates the collective purchasing power of multiple healthcare providers to negotiate contracts with manufacturers and distributors. Instead of every hospital independently negotiating prices for every product category, a GPO pools demand across hundreds or thousands of member facilities and uses that combined volume to secure pre-negotiated pricing and contract terms.
The U.S. GPO market is highly concentrated. According to MedDeviceGuide’s 2026 procurement guide, three organizations control approximately 75% of all healthcare GPO spend in the United States:
Vizient is the largest GPO in the U.S. According to Definitive Healthcare data from October 2025, Vizient has the greatest number of staffed beds with more than 468,000, covering more than 50% of the nation’s acute care providers. Members generate a combined purchase volume of $100 billion annually.
Premier Inc. unites approximately 4,100 U.S. hospitals and health systems, focusing on performance improvement and data analytics alongside supply chain contracting.
HealthTrust Purchasing Group is a subsidiary of HCA Healthcare with a purchasing power of $45 billion, delivering savings to more than 1,600 hospitals.
Beyond the big three, distributor-backed GPOs including Cardinal Health, McKesson, and Cencora serve high-volume consumable categories. Smaller specialty GPOs including Acurity, Sourcewell, and the Children’s Hospital Association serve niche segments and can offer more agility and shorter contracting cycles for new market entrants.
Approximately 72% of U.S. hospitals participate in GPO contracts. For a video laryngoscope manufacturer, GPO contract status is the first question every hospital procurement team asks. A device on a GPO contract can be purchased through a streamlined process. A device not on any GPO contract requires a separate, institution-level approval process for every single hospital.
What an IDN is and how it interacts with GPO contracts
An Integrated Delivery Network is a health system that owns and operates multiple hospitals, clinics, and care facilities under a single corporate structure. Large IDNs include HCA Healthcare with 180-plus hospitals, Ascension Health with 140-plus hospitals, CommonSpirit Health, Mayo Clinic, and Kaiser Permanente.
IDNs make procurement decisions centrally for all their facilities. A single IDN approval can open access to dozens of hospitals simultaneously. However, getting into an IDN is harder than selling to an individual hospital because the evaluation process is more rigorous, the stakeholder group is larger, and IDNs have established supplier relationships and preferred vendor lists that are difficult to displace.
IDNs typically work alongside GPOs. They may use a GPO contract as the starting point for pricing and then negotiate additional terms directly with the manufacturer. Some large IDNs have their own in-house contracting capability and negotiate directly without going through a GPO at all. As MedDeviceGuide notes, for a manufacturer seeking market access, understanding whether a target hospital system uses a GPO contract, an IDN contract, or a hybrid of both determines the entire commercial strategy.
How GPO contracts work for video laryngoscopes
GPO contracts for medical devices, including video laryngoscopes, are typically awarded through a competitive bid process. The GPO issues a request for proposal. Manufacturers respond with product specifications, clinical evidence, pricing, and value-added services. According to BuzzBox Media’s GPO marketing guide, the GPO evaluates submissions across clinical performance, total cost of ownership, service and support, and regulatory compliance before awarding contracts.
A GPO contract does not guarantee sales volume. Winning a contract makes a device eligible for purchase by GPO member hospitals. Converting that eligibility into actual purchases requires active sales engagement with individual member hospitals, clinical champion development at each institution, and value analysis committee presentations. The contract is the door. The commercial work is still required to walk through it.
GPOs earn revenue through administrative fees paid by suppliers, not by member hospitals. Under federal anti-kickback safe harbor regulations, these fees must not exceed 3% of the purchase price of the products sold to member hospitals. This fee structure means GPO contracts are commercial agreements, not regulatory approvals.
For a new market entrant like Astra-vue, gaining a GPO contract is a medium-term goal that requires demonstrating clinical adoption, building a reference account base, and assembling the documentation package that GPO category managers require. The path to a GPO contract runs through individual hospital sales, not the other way around.
How the Value Analysis Committee process works
Whether a hospital is purchasing through a GPO contract or independently, most institutions require new devices to pass through a Value Analysis Committee before clinical use. The VAC is a cross-functional committee that evaluates new product requests for formulary addition.
According to BuzzBox Media’s hospital formulary guide, the VAC process typically involves five stages:
Stage 1: Clinical sponsor submission. A clinical champion within the institution, typically an anesthesiologist, intensivist, or emergency medicine physician, submits a product request with clinical rationale and cost impact. Without an internal clinical champion, a new device rarely progresses past this stage.
Stage 2: Initial screening. The VAC screens the request against system priorities, existing contracts, and standardization goals. If the hospital already has a preferred video laryngoscope on a GPO contract, the new device must demonstrate a compelling reason to introduce a second platform.
Stage 3: Evidence review. Detailed review of clinical evidence, economic analysis, and competitive comparison. For a video laryngoscope, the ASA 2022 guidelines, the DAS 2025 first-line recommendation, the DEVICE trial published in the New England Journal of Medicine in 2023, and the 2024 JAMA cluster trial all provide the clinical evidence anchor. For a full breakdown of the procurement evidence framework, see our video laryngoscope buying guide for U.S. hospitals.
Stage 4: Clinical trial period. Most VACs require a structured in-house evaluation period before committing to a contract. Success metrics must be defined in advance: first-attempt success rate, clinician satisfaction scores, device failure incidents, and time to intubation.
Stage 5: Contract and formulary decision. If the evaluation period succeeds, the VAC approves the device for formulary addition and procurement proceeds. For a GPO-contracted device, this triggers a purchase order against the existing contract. For a non-contracted device, the VAC decision may trigger a sole-source contract or a direct purchase outside the GPO framework.
What distributors must do to navigate non-contracted hospital sales
Astra-vue is a new market entrant. It does not yet hold a contract with Vizient, Premier, or HealthTrust. This means distributors selling Astra-vue in the U.S. must navigate non-contracted hospital sales. This is a well-established pathway, not a barrier.
As MedDeviceGuide explains, hospitals can and do purchase devices outside GPO contracts when clinical justification is strong enough. The process requires more work but is entirely achievable for a device with compelling clinical evidence.
The non-contracted sales pathway has five components:
Build a clinical champion. Identify an anesthesiologist, emergency medicine physician, or intensivist at the target hospital who is receptive to evaluating a new video laryngoscope system. Provide that champion with a complete value analysis dossier including clinical evidence, economic analysis, and a comparison of total cost of ownership.
Prepare a VAC-ready documentation package. Include the following as a minimum: FDA clearance documentation with the 510(k) number, ISO 13485 certification, peer-reviewed clinical evidence supporting first-attempt success rates, a total cost of ownership analysis comparing Astra-vue against the hospital’s current system, and a structured evaluation protocol with predefined success metrics.
Propose a formal evaluation period. Most hospitals will not purchase a non-contracted device without a trial. Structure the evaluation period with defined metrics, a fixed timeline of 30 to 60 days, and a clear decision framework. Provide loaner units and full clinical support throughout the evaluation.
Use clinical evidence as the business case. The DAS 2025 guidelines, the ASA 2022 guidelines, and the DEVICE trial data are category-A level evidence anchors. A procurement team or VAC that is being asked to consider a non-contracted device needs evidence of this quality to justify the decision internally.
Address the GPO question directly. When procurement teams ask, “Are you on Vizient?” the correct answer is not to deflect but to explain the non-contracted purchasing pathway, confirm that the hospital can purchase outside GPO contracts with appropriate VAC approval, and provide documentation that supports that process.
How IDN-level sales differ from individual hospital sales
Winning a single hospital account is valuable. Winning an IDN is transformative. An IDN approval covers every facility in the network. For Astra-vue distributors targeting the U.S. market, IDN-level conversations should be a medium-term priority once a reference account base is established.
IDN procurement teams evaluate devices across four dimensions: clinical evidence quality, total cost of ownership across the network, operational standardization benefits, and supply chain reliability. For a video laryngoscope specifically, the universal monitor platform argument is powerful at IDN level. A single monitor platform that accepts reusable, disposable, and hybrid blade configurations across multiple departments reduces capital expenditure, simplifies training, and cuts inventory management complexity across the entire network.
Supply chain stability is also an IDN priority. IDNs conduct supplier due diligence on manufacturing heritage, quality certifications, and supply continuity. Astra-vue’s Goldstar Medical manufacturing foundation and ISO 13485 certification address these requirements directly.
What the current U.S. market environment means for video laryngoscope procurement
Two market dynamics are creating procurement opportunities for new video laryngoscope entrants in 2026. First, the DAS 2025 first-line recommendation and the weight of evidence from the DEVICE trial are driving departments to reassess their current video laryngoscope provision. Departments that adopted a single platform five years ago are now evaluating whether that platform meets the clinical standard the evidence now defines.
Second, the 2025 to 2026 tariff environment has raised pricing for manufacturers with high Chinese component dependency. Procurement teams facing mid-contract price adjustment notices from incumbent suppliers are more receptive to evaluating alternatives. For the full context on how tariffs are affecting U.S. video laryngoscope pricing, see our analysis of how U.S. tariffs affect video laryngoscope pricing in 2026.
For distributors evaluating the Astra-vue product line for U.S. distribution, our distributor programme guide covers what manufacturers look for, what documentation is required, and how to start the conversation. To discuss U.S. market entry directly, contact our team.
Frequently asked questions about GPO and IDN video laryngoscope procurement in the USA
What is a GPO and why does it matter for video laryngoscope procurement?
A Group Purchasing Organization negotiates contracts with medical device manufacturers on behalf of member hospitals. Approximately 72% of U.S. hospitals participate in GPO contracts. A video laryngoscope on a GPO contract can be purchased by member hospitals through a streamlined process. A device not on a GPO contract requires a separate institution-level approval process through the hospital’s Value Analysis Committee.
Can a hospital buy a video laryngoscope that is not on a GPO contract?
Yes. Hospitals can purchase devices outside GPO contracts when clinical justification is strong enough. The process requires VAC approval, a clinical champion, a complete evidence dossier, and typically a structured evaluation period. Non-contracted purchases are common for new or innovative products that have not yet established GPO contract positions.
What do the three major U.S. GPOs cover for video laryngoscopes?
Vizient, Premier, and HealthTrust collectively represent approximately 75% of U.S. healthcare GPO spend. Each maintains a portfolio of contracted medical device suppliers across equipment categories including airway management devices. A manufacturer with a contract across all three major GPOs has potential access to the majority of U.S. acute care hospitals through a single contracting framework.
What is an IDN and how does it differ from a GPO for procurement purposes?
An Integrated Delivery Network is a health system that owns multiple hospitals and makes procurement decisions centrally for all its facilities. A GPO negotiates contracts on behalf of member hospitals that remain independently operated. IDNs may use GPO contracts as a pricing baseline but often negotiate additional terms directly. Winning an IDN approval opens access to every facility in the network simultaneously.
How long does the VAC approval process typically take for a video laryngoscope?
Timelines vary by institution. A device already on a GPO contract that the hospital uses may take 4 to 8 weeks for VAC approval. A non-contracted device requiring a full clinical evaluation and financial analysis typically takes 3 to 6 months or longer. Institutions with established formulary processes and an active clinical champion move faster than those without internal sponsorship.
